42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. (5th March 2018) - Harb, W; Abramson, J; Lunning, M; Goy, A; Maddocks, K; Lebedinsky, C; Senderowicz, A; Trojer, P; Bradley, W D; Flinn, I